Effects of Secukinumab combined with narrow-band UVB in treatment of patients with moderate to severe psoriasis
Objective:To observe effects of Secukinumab combined with narrow-band UVB in treatment of patients with moderate to severe psoriasis.Methods:The clinical data of 108 patients with moderate to severe psoriasis admitted to this hospital from March 2022 to March 2023 were retrospectively analyzed.According to different treatment methods,they were divided into observation group and control group,54 cases in each group.The control group was treated with narrow-band UVB local irradiation,while the observation group was treated with Secukinumab injection on the basis of that of the control group.The total effective rate of treatment,the psoriasis area and severity index(PASI)score,the pruritus visual analogue scale(VAS)score,the inflammatory factors[interleukin(IL)-2,IL-4,IL-10,interferon-γ(INF-γ)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 92.59%,which was higher than 77.78%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the PASI and VAS scores,and the serum IL-2 and INF-γ levels in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of serum IL-4 and IL-10 in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Secukinumab combined with narrow-band UVB in the treatment of the patients with moderate to severe psoriasis can improve the total effective rate of treatment,reduce the PASI levels and the VAS scores,and improve the levels of inflammatory factors.Moreover,it is superior to single narrow-band UVB treatment.
PsoriasisSecukinumabNarrow-band UVBInflammatory factorPsoriasis area and severity indexVisual analogue scaleAdverse reaction
万方数据
维普
